title: Angiotensin-(1-7) attenuates hypertension in exercise-trained renal hypertensive rats.
abstract: Angiotensin-(1-7) [ANG-(1-7)] plays a counterregulatory role to angiotensin II in the renin-angiotensin system. In trained spontaneous hypertensive rats, Mas expression and protein are upregulated in ventricular tissue. Therefore, we examined the role of ANG-(1-7) on cardiac hemodynamics, cardiac functions, and cardiac remodeling in trained two-kidney one-clip hypertensive (2K1C) rats. For this purpose, rats were divided into sedentary and trained groups. Each group consists of sham and 2K1C rats with and without ANG-(1-7) infusion. Swimming training was performed for 1 h/day, 5 days/wk for 4 wk following 1 wk of swimming training for acclimatization. 2K1C rats showed moderate hypertension and left ventricular hypertrophy without changing left ventricular function. Chronic infusion of ANG-(1-7) attenuated hypertension and cardiac hypertrophy only in trained 2K1C rats but not in sedentary 2K1C rats. Chronic ANG-(1-7) treatment significantly attenuated increases in myocyte diameter and cardiac fibrosis induced by hypertension in only trained 2K1C rats. The Mas receptor, ANG II type 2 receptor protein, and endothelial nitric oxide synthase phosphorylation in ventricles were upregulated in trained 2K1C rats. In conclusion, chronic infusion of ANG-(1-7) attenuates hypertension in trained 2K1C rats.
authors.affiliation: Department of Physiology, Research Center for Endocrine Sciences, Chonbuk National University Medical University, Jeonju, Korea.
authors.forename: Amin
authors.initials: A
authors.lastname: Shah
authors.forename: Young-Bin
authors.initials: YB
authors.lastname: Oh
authors.forename: Sun Hwa
authors.initials: SH
authors.lastname: Lee
authors.forename: Jung Min
authors.initials: JM
authors.lastname: Lim
authors.forename: Suhn Hee
authors.initials: SH
authors.lastname: Kim
mesh_terms: D000803:Angiotensin I / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006352:Heart Ventricles / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D006977:Hypertension, Renal / Q000503:physiopathology* / Q000517:prevention & control*; D017379:Hypertrophy, Left Ventricular / Q000473:pathology / Q000517:prevention & control; D007668:Kidney / Q000503:physiopathology / Q000601:surgery; D008297:Male; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D010805:Physical Conditioning, Animal / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044139:Receptor, Angiotensin, Type 2 / Q000378:metabolism; D013525:Surgical Instruments; D013550:Swimming / Q000502:physiology*
chemical_list: D000959:Antihypertensive Agents; D002316:Cardiotonic Agents; D010446:Peptide Fragments; D044139:Receptor, Angiotensin, Type 2; D000803:Angiotensin I; D052250:Nitric Oxide Synthase Type III; C118790:angiotensin I (1-7)